Cadila Healthcare moves up on the BSE
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Cadila Healthcare is currently trading at Rs. 448.15, up by 8.30 points or 1.89% from its previous closing of Rs. 439.85 on the BSE.
The scrip opened at Rs. 442.10 and has touched a high and low of Rs. 449.85 and Rs. 441.00 respectively. So far 78240 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 509.35 on 15-Jan-2021 and a 52 week low of Rs. 290.10 on 07-Apr-2020.
Last one week high and low of the scrip stood at Rs. 449.85 and Rs. 433.25 respectively. The current market cap of the company is Rs. 45751.06 crore.
The promoters holding in the company stood at 74.88%, while Institutions and Non-Institutions held 16.96% and 7.97% respectively.
Zydus Cadila has sought approval from the domestic drug regulator Drugs Controller General of India (DCGI) for additional indication of its hepatitis drug Pegylated Interferon Alpha-2b for treating COVID-19. Phase-III clinical trials with Pegylated Interferon Alpha 2b, which company sells under the brand name 'PegiHep' has shown promising results in treating COVID-19.
The treatment regimen would be less cumbersome and more affordable for patients as Pegylated Interferon Alpha 2b, is a single dose regimen. It would also ensure better compliance.
Cadila Healthcare is an India-based pharmaceutical company. The company's subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others.
